Olema Pharmaceuticals (OLMA) Competitors $8.35 +0.18 (+2.19%) Closing price 09/22/2025 03:58 PM EasternExtended Trading$8.52 +0.17 (+2.00%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA vs. ANIP, RXRX, TVTX, BEAM, TARS, IRON, DNLI, ARQT, ADPT, and MESOShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include ANI Pharmaceuticals (ANIP), Recursion Pharmaceuticals (RXRX), Travere Therapeutics (TVTX), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Denali Therapeutics (DNLI), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Olema Pharmaceuticals vs. Its Competitors ANI Pharmaceuticals Recursion Pharmaceuticals Travere Therapeutics Beam Therapeutics Tarsus Pharmaceuticals Disc Medicine Denali Therapeutics Arcutis Biotherapeutics Adaptive Biotechnologies Mesoblast Olema Pharmaceuticals (NASDAQ:OLMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk. Do analysts recommend OLMA or ANIP? Olema Pharmaceuticals presently has a consensus price target of $24.00, suggesting a potential upside of 187.46%. ANI Pharmaceuticals has a consensus price target of $93.00, suggesting a potential downside of 3.05%. Given Olema Pharmaceuticals' higher possible upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11 Which has stronger earnings and valuation, OLMA or ANIP? ANI Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$129.47M-$1.98-4.22ANI Pharmaceuticals$614.38M3.39-$18.52M-$0.77-124.58 Which has more volatility & risk, OLMA or ANIP? Olema Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Is OLMA or ANIP more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.37%. ANI Pharmaceuticals' return on equity of 25.03% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -42.58% -38.65% ANI Pharmaceuticals -1.37%25.03%8.00% Does the media prefer OLMA or ANIP? In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 8 mentions for Olema Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.95 beat Olema Pharmaceuticals' score of 0.12 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in OLMA or ANIP? 91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 16.4% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryANI Pharmaceuticals beats Olema Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$560.74M$3.16B$5.79B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-4.2221.03348.8626.86Price / SalesN/A447.99555.40125.65Price / CashN/A44.8326.0131.15Price / Book1.179.8315.996.50Net Income-$129.47M-$52.82M$3.29B$271.25M7 Day Performance5.82%3.07%200.40%3.27%1 Month Performance44.95%5.37%184.31%8.15%1 Year Performance-35.68%16.89%331.44%26.52% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals2.7644 of 5 stars$8.35+2.2%$24.00+187.5%-38.8%$560.74MN/A-4.2270ANIPANI Pharmaceuticals4.0224 of 5 stars$98.81+1.1%$88.25-10.7%+60.8%$2.12B$614.38M-128.32600RXRXRecursion Pharmaceuticals2.3347 of 5 stars$4.77-1.2%$7.25+52.0%-26.8%$2.10B$58.84M-2.68400Positive NewsGap UpTVTXTravere Therapeutics2.7163 of 5 stars$23.01-2.0%$34.20+48.6%+67.2%$2.09B$233.18M-11.28460Analyst DowngradeBEAMBeam Therapeutics2.9941 of 5 stars$21.28+3.3%$46.40+118.0%-4.8%$2.08B$63.52M-4.73510TARSTarsus Pharmaceuticals2.1623 of 5 stars$49.59+0.5%$66.67+34.4%+61.2%$2.08B$182.95M-21.2850IRONDisc Medicine3.2308 of 5 stars$59.90+0.1%$98.30+64.1%+27.8%$2.08BN/A-13.4030Positive NewsDNLIDenali Therapeutics4.2639 of 5 stars$13.16-7.3%$33.50+154.6%-56.9%$2.07B$330.53M-4.70430ARQTArcutis Biotherapeutics2.1789 of 5 stars$16.93-2.1%$19.80+17.0%+71.2%$2.07B$196.54M-22.57150ADPTAdaptive Biotechnologies3.4145 of 5 stars$13.08+3.7%$12.38-5.4%+199.8%$1.92B$205.22M-15.95790Positive NewsMESOMesoblast0.992 of 5 stars$15.46+4.3%$18.00+16.4%+146.0%$1.90B$17.20M0.0080Positive NewsGap Up Related Companies and Tools Related Companies ANIP Alternatives RXRX Alternatives TVTX Alternatives BEAM Alternatives TARS Alternatives IRON Alternatives DNLI Alternatives ARQT Alternatives ADPT Alternatives MESO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OLMA) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OLMA Stock Alerts